Osivax

Osivax is a clinical-stage biopharmaceutical company based in Lyon, France, with additional locations in Liège, Belgium, and Australia. Founded in 2017 as a spin-off from Imaxio, Osivax specializes in developing universal vaccines aimed at highly mutating respiratory viruses. The company utilizes its proprietary oligoDOM™ self-assembling nanoparticle platform, which effectively targets both T-c...